For example, anti-PD-1/L1 therapy combined with anti-CTLA4 has become the standard for the treatment of melanoma, and the combination of nivolumab and ipilimumab in patients with advanced melanoma can improve the survival rate of patients of 5 years [51]. The gene discussed is CTLA4; the disease is melanoma.